ClinicalTrials.gg
Active, not recruitingNCT05758909FAST TRACKUpdated Dec 19, 2025

Evaluation of the Viability and Safety of Early Discharge Protocol After TAVI Implantation

An observational study in Aortic Valve Disease, Aortic Valve Stenosis and Heart Valve Diseases, sponsored by Fundación EPIC. Active, not recruiting at 13 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-19.

Primary conditionAortic Valve StenosisRegistry: Aortic Valve DiseaseReclassifiedWhy we changed it
Registry
Aortic Valve Disease — the first condition term the registry derived for this study.
ClinicalTrials.gg
Aortic Valve Stenosis
Why
  1. The study's listed conditions name Aortic Valve Stenosis, a narrower term within Aortic Valve Disease.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Fundación EPIC · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
585
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 83 studies in Aortic Valve Stenosis with a site in Spain — 25 open to participants now, 32 under way, 1 of them phase 3. Aortic Valve Stenosis · Spain.

Planned enrollment
18th of 46
585 · median 373
Started
2023
with 8 others
Observational
46 of 83
9 open now
Primary completion
2026-12
later than 16 of 31 live
Registered
61st of 83
by date
Lead sponsor
4 of 83
Fundación EPIC

Among the 83 studies in Aortic Valve Stenosis with a site in Spain, this one is the 18th largest by planned enrollment of the 46 observational ones that give a count, is one of 9 that started in 2023, is one of 46 observational ones, reaches primary completion later than 16 of the 31 other live ones, and was the 61st registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

25 of the 83 studies in Aortic Valve Stenosis with a site in Spain are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Aortic Valve Stenosis with a site in Spain, or all of them as a file.
02

Study summary

Evaluation of the safety and efficacy of early discharge (24 hours) after transfemoral transcatheter aortic prosthesis implantation (TAVI).

Read the detailed description

Evaluation of the safety and efficacy of early discharge (24 hours) after transfemoral transcatheter aortic prosthesis implantation (TAVI).

03

Conditions studied

  • Aortic Valve Disease
  • Aortic Valve Stenosis
  • Heart Valve Diseases

Browse trials for

04

In context

Aortic Valve Stenosis Reclassified

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

This study's planned enrollment of 585 is above the median of 200 across 437 observational studies indexed under Aortic Valve Stenosis.

Browse Aortic Valve Stenosis studies →

Lead sponsor

Fundación EPIC is the lead sponsor of 48 studies on the registry; 19 are open to participants now.

Compared within Aortic Valve Stenosis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Aortic Valve Disease. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Probability sample

Study population

Patients undergoing scheduled transfemoral TAVI implantation, performed on an outpatient basis

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients who meet all of the following conditions will be included:

  • Patients ≥ 18 years undergoing transfemoral TAVI implantation scheduled, performed on an outpatient basis.
  • Patients with percutaneous implant.
  • Patients undergoing the procedure under superficial sedation or Local anesthesia.
  • Patients with baseline narrow QRS that does not change after implantation, or definitive pacemaker carrier.
  • Patients who have signed the .

Exclusion criteria

Exclusion Criteria:

Patients who do not meet any of the following conditions:

  • Patients with a wide QRS (greater than or equal to 120 msec) at baseline, with the except for patients with permanent pacemakers.
  • Hospitalized patients undergoing urgent TAVI implantation.
  • Patients with access other than percutaneous transfemoral.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
585 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • Patients receiving transfemoral (TF) TAVI

    TF TAVI

    Device: TF TAVI

Interventions

  • DeviceTF TAVI

    Follow-up Observation of patients having received a TF-TAVI

07

What researchers measure

Primary outcomes

  1. Assessment of early safety

    Proportion of patients with early safety defined as: * Cardiovascular death. * Stroke. * Myocardial Infarction. * Hospitalization for any reason . * Major vascular complications. * Need for pacemakers.

    Time frame: 30 days

Secondary outcomes

  1. Assessment of Cardiovascular death

    Assessment of Cardiovascular death

    Time frame: 30 days

  2. Assessment of Cardiovascular death

    Assessment of Cardiovascular death

    Time frame: 12 months

  3. Assessment of Stroke

    Incidence of patients with stroke diagnosed by a Neurologist according to VARC 3 criteria

    Time frame: 30 days

  4. Assessment of Stroke

    Incidence of patients with stroke diagnosed by a Neurologist according to VARC 3 criteria

    Time frame: 12 months

  5. Assessment of Myocardial Infarction

    Incidence of patients with Myocardial Infarction diagnosed by Cardiologist according to VARC 3 criteria

    Time frame: 30 days

  6. Assessment of Myocardial Infarction

    Incidence of patients with Myocardial Infarction diagnosed by Cardiologist according to VARC 3 criteria

    Time frame: 12 months

  7. Assessment of Hospitalization for any reason

    Incidence of patients with Hospitalization for any reason according to VARC 3 criteria

    Time frame: 30 days

  8. Assessment of Hospitalization for any reason

    Incidence of patients with Hospitalization for any reason according to VARC 3 criteria

    Time frame: 12 months

  9. Assessments of Major Vascular Complications

    Incidence of patients with Major Vascular Complications according to VARC 3 criteria

    Time frame: 30 days

  10. Assessments of Major Vascular Complications

    Incidence of patients with Major Vascular Complications according to VARC 3 criteria

    Time frame: 12 months

  11. Assessments of need for pacemakers

    Incidence of patients with need for pacemakers according to VARC 3 criteria

    Time frame: 30 days

  12. Assessments of need for pacemakers

    Incidence of patients with need for pacemakers according to VARC 3 criteria

    Time frame: 12 months

  13. Assessment of hospitalization time

    Incidence of patients with hospitalization according to VARC 3 criteria

    Time frame: at discharge

  14. Assessment of hospitalization due cardiac reasons

    Incidence of patients with hospitalization due cardiac reasons according to VARC 3 criteria

    Time frame: 12 months

  15. Assessment of hospitalization due cardiac reasons

    Incidence of patients with hospitalization due cardiac reasons according to VARC 3 criteria

    Time frame: 30 days

08

Study locations

13 sites
09

References and documents

Publications

  • Barbanti M, van Mourik MS, Spence MS, Iacovelli F, Martinelli GL, Muir DF, Saia F, Bortone AS, Densem CG, van der Kley F, Bramlage P, Vis M, Tamburino C. Optimising patient discharge management after transfemoral transcatheter aortic valve implantation: the multicentre European FAST-TAVI trial. EuroIntervention. 2019 Jun 20;15(2):147-154. doi: 10.4244/EIJ-D-18-01197. PubMed 30777842 ↗
  • van Gils L, Baart S, Kroon H, Rahhab Z, El Faquir N, Rodriguez Olivares R, Aga Y, Maugenest AM, Theuns DA, Boersma E, Szili Torok T, De Jaegere PP, Van Mieghem NM. Conduction dynamics after transcatheter aortic valve implantation and implications for permanent pacemaker implantation and early discharge: the CONDUCT-study. Europace. 2018 Dec 1;20(12):1981-1988. doi: 10.1093/europace/euy074. PubMed 29688322 ↗
  • Aldalati O, Keshavarzi F, Kaura A, Byrne J, Eskandari M, Deshpande R, Monaghan M, Wendler O, Dworakowski R, MacCarthy P. Factors associated with safe early discharge after transcatheter aortic valve implantation. Cardiol J. 2018;25(1):14-23. doi: 10.5603/CJ.a2017.0087. Epub 2017 Jul 17. PubMed 28714522 ↗
  • Serletis-Bizios A, Durand E, Cellier G, Tron C, Bauer F, Glinel B, Dacher JN, Cribier A, Eltchaninoff H. A Prospective Analysis of Early Discharge After Transfemoral Transcatheter Aortic Valve Implantation. Am J Cardiol. 2016 Sep 15;118(6):866-872. doi: 10.1016/j.amjcard.2016.06.035. Epub 2016 Jun 27. PubMed 27453514 ↗
  • Chandrasekhar J, Mehran R. Same or next day discharge: A new chapter in transcatheter aortic valve implantation. Catheter Cardiovasc Interv. 2016 Jan 1;87(1):143-4. doi: 10.1002/ccd.26388. PubMed 27410958 ↗
  • Wood DA, Lauck SB, Cairns JA, Humphries KH, Cook R, Welsh R, Leipsic J, Genereux P, Moss R, Jue J, Blanke P, Cheung A, Ye J, Dvir D, Umedaly H, Klein R, Rondi K, Poulter R, Stub D, Barbanti M, Fahmy P, Htun N, Murdoch D, Prakash R, Barker M, Nickel K, Thakkar J, Sathananthan J, Tyrell B, Al-Qoofi F, Velianou JL, Natarajan MK, Wijeysundera HC, Radhakrishnan S, Horlick E, Osten M, Buller C, Peterson M, Asgar A, Palisaitis D, Masson JB, Kodali S, Nazif T, Thourani V, Babaliaros VC, Cohen DJ, Park JE, Leon MB, Webb JG. The Vancouver 3M (Multidisciplinary, Multimodality, But Minimalist) Clinical Pathway Facilitates Safe Next-Day Discharge Home at Low-, Medium-, and High-Volume Transfemoral Transcatheter Aortic Valve Replacement Centers: The 3M TAVR Study. JACC Cardiovasc Interv. 2019 Mar 11;12(5):459-469. doi: 10.1016/j.jcin.2018.12.020. PubMed 30846085 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Dec 2026, 43 months after the start.

Of 206 non-industry observational studies under Aortic Valve Stenosis, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 120. This study's planned 43 months is close to that.

Counting every sponsor, half of 243 studies reached it within 44 months; a quarter within 23 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2023
First posted
Mar 8, 2023
StartActual
Apr 4, 2023
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Dec 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05758909
Lead sponsor
Fundación EPIC
Responsible party
Sponsor
First posted
Mar 8, 2023
Start date
Apr 4, 2023
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Dec 19, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion